Parabilis Medicines to present zolucatetide desmoid tumor data at ESMO Congress 2026
The company disclosed plans for an oral presentation of updated Phase 1/2 trial results in Madrid on October 24, 2026.
Parabilis Medicines, Inc. filed an 8-K dated September 15, 2026, disclosing a change to its guidance regarding upcoming data disclosures. The company said it now intends to present updated clinical data from its ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026, to be held in Madrid, Spain.1
The presentation is scheduled for Saturday, October 24, as part of a sarcoma-focused Proffered Paper session set to begin at 2:45pm CEST, or 8:45am ET.1
The disclosure was made under Item 7.01 of the filing, covering Regulation FD matters. Parabilis noted that this information is being furnished rather than filed for purposes of Section 18 of the Exchange Act, and will not be incorporated by reference into other securities filings unless specifically stated.1
The filing was signed by Thomas Kotarakos, the company's Chief Financial Officer, on September 15, 2026. No additional clinical results, dosing details, or efficacy figures were included in this filing itself; the company indicated these would be shared at the ESMO presentation in October.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.